

# Progress in drug access and development for AMR

## Welcome to The AMR Global Health Academy Newsletter May 2025

[The AMR Global Health Academy](#) serves the global health professional and antimicrobial steward in low- and middle-income countries with a free online educational curriculum designed to advance AMR knowledge and best practices. Every month, via the Newsletter, we share important updates from the AMR field, especially as it relates to AMR testing, diagnostics, and surveillance. We feature news stories, articles, events, resources, and AMR champions battling the real-world AMR problems.

[The AMR Academy](#) has numerous courses and educational activities designed to empower AMR stewards, particularly global health professionals from LMICs. We recently launched the first in our 2025 [AMR Problem Solving Case Study series](#) (soon available in French, Portuguese, and Spanish). You may be familiar with these from [last year](#). This year we are focusing on the community and journalism to drive action against AMR.

To join the AMR Global Health Academy, enroll in the Global Health Continuing Professional Development (GHCPD) free online AMR courses [here](#).

### ***AMR GHCPD Faculty***

Global Health Continuing Professional Development (GHCPD) faculty are global and regional experts in their field and drive the educational curriculum to ensure information is relevant, pertinent, and applicable to the needs of learners from low resource settings. Here we would like to profile a faculty member who generously continues to support the GHCPD educational platform.



**Mr. Carlos Gouvea** contributed to the formation of the AMR Global Health Academy and is involved in all AMR courses to ensure the materials are relevant to the Portuguese speaking community and the Latin American/Brazil region. He has organized numerous launches in collaboration with Brazilian partners and professional organizations (e.g. SBAC). Carlos Eduardo Gouvêa, graduated in Public Administration (EAESP/FGV – Brazil) and Law (University of São Paulo) and holds a MBA degree (OneMBA – University of North Carolina, Erasmus Universiteit, University of China in Hong Kong, Tec de Monterrey and FGV – Fundação Getúlio Vargas). After a short experience in the legal area,

focusing on Corporate Law at O'Melveny & Myers and Goulart Pentead, Iervolino & Lefosse (Linklaters), he worked in Marketing at Unilever and at Courtaulds, before joining Coopers & Lybrand. In the healthcare area, he has held positions as Diagnostic Business Manager at Organon Teknika (Akzo Nobel) and CEO of Support and Mococa (Royal Numico,, nowadays Danone). Since 2005, he has been a Managing Partner at Green Hill Consulting, focused on the healthcare area with interests in start-ups, being also responsible, as Managing Director, for CMW Saúde, a company dedicated to specialized nutrition in Latin America. Currently, he is in charge of several associations, in different positions: Executive President at CBDL (Brazilian Chamber for In Vitro Diagnostics) and Vice-President at ABIIS (Brazilian Alliance for Innovative Healthcare Industry). He is also a founding member and President of ALADDIV – The Latin American Alliance for the Development of In Vitro Diagnostics and acts as Member of the Advisory Boards of FBAH – Brazilian Federation of Hospital Administrators, INAC – Institute Against Corruption, IES – Ethics Health Institute, ComSaúde – Committee of the Industrial and Productive Complex of Health and Biotechnology of the São Paulo State Industry Federation and, also, of the FIT – Parliamentary Front of Integrity and Transparency.

## News Story

*Lowering prices of pretomanid (<\$1/day), a key drug for drug resistant TB*



**Source:** TB Alliance. "Price of Key DR-TB Medicine Drops 25% as TB Alliance's Multi-Manufacturer Strategy Expands Access." TB Alliance, 20 May 2024, <https://www.tballiance.org>.


Treating drug resistant tuberculosis can be challenging and requires a six-month treatment regimen consisting of bedaquiline, pretomanid, and linezolid, with or without moxifloxacin (BPAL/M). However, the price of pretomanid alone was over \$350 per treatment course in 2019. Since then, the TB Alliance initiated an innovative access model to reduce the price of pretomanid by partnering with multiple quality-assured manufacturers to improve competition and ensure multiple high-quality supply sources are available.

Pretomanid and BPAL/M are available through the Global Drug Facility (GDF) at a total treatment cost of \$169. Hopefully this lower cost will expand availability and access to this critical drug for those with drug resistant TB.

The SLASH-TB (Savings from Leveraging & Adopting Shorter & Highly Effective TB Treatments) is a model to estimate cost savings when using BPAL/M. See [here](#) if interested to use this model.

# Article Spotlight

*A new drug available for the treatment of uncomplicated urogenital gonorrhoea*



*Neisseria gonorrhoeae* remains a public health threat, particularly affecting antimicrobial resistance with persistent resistance to the last treatment option, ceftriaxone, in several countries and regions around the world. A new [study](#) recently published in the *Lancet* provided the results of the EAGLE-1 phase 3, open-label, sponsor-blinded, multicentre, non-inferiority study. Oral gepotidacin was found to be non-inferior to ceftriaxone plus azithromycin in the treatment of uncomplicated urogenital gonorrhoea – presenting a new treatment option.

An accompanying [comment](#) was published in the *Lancet* to provide a contextual public health perspective.

Though these advances of progress are promising, a recent [comment](#) in *Lancet Infectious Diseases* continues to highlight that more work needs to be done. A recent [study](#) in *Lancet Infectious Diseases* found persistent undertreatment of carbapenem-resistant Gram-negative bacterial infections in several LMICs.

The comment suggested a few key next steps in the fight against AMR:

- Settings clear, practical, and ambitious patient-centered targets, rather than prescription-centered.
- Universal testing before treatment, including once accurate point-of-care diagnostics are available to detect AMR.
- Ensuring access to appropriate antimicrobials in all countries at an affordable price.

## Creating AMR Awareness

The [Science for Africa Foundation](#) has launched a journalism competition to celebrate impactful and compelling stories, features, or campaigns that raise awareness and educate the public on AMR. The goal is to inspire behavior change and amplify the role of media in protecting public health. Call for applications can be found [here](#). Deadline: 4 July 2025, 1700HRS, East African Time (EAT).

The [GHCPD platform](#) consistently presents new research and innovations in diagnostics and



testing to drive AMR awareness.

# In Case You Missed It

WHO recently published the “*Global Antimicrobial Resistance and Use Surveillance System (GLASS) report: antibiotic use data for 2022*”. See [here](#) for the report.

On 30 April 2025, Sepsis Alliance hosted a 1-day virtual discussion of AMR- and sepsis-focused diagnostics, therapeutics, and advocacy. See [here](#) for more details.

In broader news, WHO Member States concluded negotiations to draft a Pandemic Agreement in an effort to increase equity, protect populations from suffering and death, and improve global collective health security together. See [here](#) for more. An [editorial](#) in the *Lancet* provided additional perspective.

# Don't Miss

The Global AMR Innovators Conference (GAMRIC) – previously the ESCMID-ASM Joint Conference on Drug Development for AMR – will be held 1 – 3 Oct 2025 in London, UK. See [here](#) for initial details. Registration opened on 5 May 2025.

ICARe (Interdisciplinary Course on Antibiotics and Resistance) will be held 11-19 October 2025 in Annecy, France. See [here](#) for details. Application deadline closes 21 June 2025.

IDWeek 2025, the annual meeting of the Infectious Diseases Society of America will be held 19-22 October 2025 in Georgia, USA. See [here](#) for details.

The journal *Antibiotics* is planning for a special issue entitled, “Antibiotics: Utilization, Resistance, and Infection Prevention”. The editors are inviting submissions for this special issue that addresses various aspects of AMR, including its mechanisms, transmission dynamics, and global impact. Manuscript submissions are due 31 October 2025. Please see [here](#) for more information.

The 10<sup>th</sup> AMR Conference 2026 will be held 3-4 March 2026 in Basel, Switzerland. Once available, details will be [here](#).

ESCMID Global 2026, the annual meeting of the European Society for Clinical Microbiology and Infectious Diseases, will be held 17-21 April 2026 in Munich, Germany. See [here](#) for more.

# What's Next

AMR poses a considerable challenge to our existing treatment regimens; however, as progress is made to identify new potential drugs and provide those at reasonable and accessible prices, further discussion on the most impactful global and national targets should be considered.

*Support for this initiative has been provided through an unrestricted educational grant from bioMérieux.*